Valuation: IRLAB Therapeutics AB

Market Cap 274M 27.42M 24.15M 22.84M 20.7M 38.88M 2.64B 39.23M 106M 1.34B 103M 101M 4.34B P/E 2026 *
-
P/E 2027 * -
Enterprise Value 274M 27.42M 24.15M 22.84M 20.7M 38.88M 2.64B 39.23M 106M 1.34B 103M 101M 4.34B EV / Sales 2026 *
2.7x
EV / Sales 2027 * 1.91x
Free-Float
83.4%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 63 2024-07-31
Corporate Officer/Principal 60 2012-12-31
Chief Tech/Sci/R&D Officer 65 2015-12-31
Director TitleAgeSince
Director/Board Member 68 2015-12-31
Chairman 73 2020-05-06
Director/Board Member 40 2022-12-31
Change 5-day change 1-year change 3-year change Capi.($)
-0.01%+1.69%+63.50%+117.58% 1,056B
-1.61%-0.71%+48.89%+70.56% 655B
-1.12%-0.45%+19.35%+72.93% 471B
-1.72%-4.25%+37.79%+39.89% 342B
-0.40%+4.12%+22.89%+29.04% 277B
-0.51%-1.05%+12.98%+12.92% 257B
+1.32%+7.75%+55.19%+56.43% 226B
-0.61%+0.48%+34.95%+100.58% 189B
-0.24%-3.21%-27.79%-61.37% 170B
Average -0.54%+0.52%+29.75%+48.73% 404.77B
Weighted average by Cap. -0.63%+0.76%+39.85%+68.92%

Financials

2026 *2027 *
Net sales 101M 10.14M 8.93M 8.45M 7.66M 14.38M 975M 14.51M 39.02M 497M 38.13M 37.3M 1.61B 143M 14.35M 12.64M 11.95M 10.84M 20.35M 1.38B 20.53M 55.22M 703M 53.96M 52.78M 2.27B
Net income -36.1M -3.62M -3.19M -3.01M -2.73M -5.13M -348M -5.18M -13.92M -177M -13.6M -13.31M -573M 34.6M 3.47M 3.05M 2.89M 2.62M 4.92M 333M 4.96M 13.34M 170M 13.04M 12.75M 549M
Net Debt - -
Logo IRLAB Therapeutics AB
IRLAB Therapeutics AB is a Sweden-based research and development company. It focuses on illnesses in the central nervous system and primarily on development of drugs to assist patients with Parkinson’s disease. The Company possesses a research platform Integrative Screening Process (ISP), which aims to discover and develop drug candidates for the treatment of brain diseases. The Company operates projects on both clinical phase and preclinical phases. The primary projects are IRL790 and IRL752, both on clinical phase. The IRL790 project is a psychomotor stabilizer for the treatment of levodopa (L-dopa) amino acid that dyskinesia induces in Parkinson’s Disease (PD-LIDs) and Parkinson Disease psychosis (PD-Psychosis). The IRL752 project aims at cortical enhancement for the treatment of Parkinson Disease Dementia (PD-D) and Behavioral and Psychological Symptoms of Dementia (BPSD).
Employees
-